.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
US Department of Justice
Citi
AstraZeneca
Mallinckrodt
Novartis
Baxter
US Army
UBS
Johnson and Johnson

Generated: December 17, 2017

DrugPatentWatch Database Preview

ENJUVIA Drug Profile

« Back to Dashboard

When do Enjuvia patents expire, and what generic alternatives are available?

Enjuvia is a drug marketed by Teva Branded Pharm and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-001Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-002Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-004May 10, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-001Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-002Dec 20, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-005Apr 27, 2007DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-005Apr 27, 2007DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-004May 10, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
Teva Branded PharmENJUVIAestrogens, conjugated synthetic bTABLET;ORAL021443-003May 10, 2004DISCNNoNo► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: ENJUVIA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe ENJUVIA ► Subscribe

Non-Orange Book Patents for Tradename: ENJUVIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,454Estrogenic compounds, pharmaceutical compositions and formulations comprising the same► Subscribe
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method► Subscribe
7,989,436Estrogenic compounds and pharmaceutical formulations comprising the same► Subscribe
7,459,445Estrogenic compounds and topical pharmaceutical formulations of the same► Subscribe
7,749,989Estrogenic compounds, methods of using and methods of administering the same► Subscribe
7,179,799(3) and (6) substituted estrogenic compounds► Subscribe
6,844,334 (3) and (6) substitued estrogenic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENJUVIA

Country Document Number Estimated Expiration
MexicoPA02008856► Subscribe
World Intellectual Property Organization (WIPO)0168669► Subscribe
Australia4541701► Subscribe
South Korea100804224► Subscribe
World Intellectual Property Organization (WIPO)0168074► Subscribe
European Patent Office1263770► Subscribe
Germany60131253► Subscribe
Australia4733701► Subscribe
Canada2402559► Subscribe
Australia2001245417► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Accenture
Covington
Citi
Boehringer Ingelheim
Federal Trade Commission
Moodys
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot